Pharmacosmos A/S — China drug registrations and re-registration deadlines
6 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest re-registration deadline: 2026-11-22.
| Approval number | Product | Certificate expires | Re-registration deadline (Art. 82) |
|---|---|---|---|
| 国药准字HJ20170106 | CosmoFer 右旋糖酐铁注射液 | 2027-05-22 | 2026-11-22 |
| 国药准字HJ20170107 | CosmoFer 右旋糖酐铁注射液 | 2027-05-22 | 2026-11-22 |
| 国药准字HJ20220066 | Trilaciclib Hydrochloride for Injection 注射用盐酸曲拉西利 | 2027-07-11 | 2027-01-11 |
| 国药准字HJ20210005 | Iron Isomaltoside Injection 异麦芽糖酐铁注射液 | 2030-12-16 | 2030-06-16 |
| 国药准字HJ20210006 | Iron Isomaltoside Injection 异麦芽糖酐铁注射液 | 2030-12-16 | 2030-06-16 |
| 国药准字HJ20210007 | Iron Isomaltoside Injection 异麦芽糖酐铁注射液 | 2030-12-16 | 2030-06-16 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.